4D-MRI for Precision Medicine

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-82
SponsorUniversity of Virginia

About this trial

The purpose of this study is to develop new ways to make medical images of the lungs and liver of adults using a technique called four-dimensional magnetic resonance imaging (4D-MRI). This technique produces three-dimensional movies of the inside of the chest and abdomen while the patient is breathing. (The fourth dimension is time!)

This new way of medical imaging is being developed to help cancer patients undergoing radiation therapy. Radiation therapy is used to treat cancerous tumors. For radiation therapy to be effective, the precise size, shape, and location of the tumor within the body must be known. A particular difficulty for radiation treatment of lung and liver cancer is that the tumor moves during treatment because the patient is breathing. Therefore, tumor motion must also be incorporated into the treatment plan. This study aims to improve radiation treatment planning through better targeting and dose estimation based on 4D-MRI. Before this new imaging method can be used for radiation treatment planning, it must be tested in living, breathing volunteers.

Eligibility criteria

Qualifiers

Patient is 21 or older

Patient has primary or metastatic tumor(s) in the lungs or the liver

Diameter of the tumor(s) is less than 7 cm

Patient will receive radiation therapy (ordered by the treating Radiation Oncologist) as part of their treatment regimen

Disqualifiers

Any condition for which a MRI procedure is contraindicated including presence of metallic material in the body, such as pacemakers, non- MRI compatible surgical clips, shrapnel, etc.

Subjects who have difficulty lying flat on their back for extended periods of time

Patients with any serious/poorly controlled medical or psychological conditions that would complicate protocol compliance

Too large to adequately fit in the magnet bore or RF coils

Trial design

Treatments tested in this trial

  • Magnetic Resonance Imaging

Treatment groups

100 Participants
are divided into 3 treatment groups

Sponsors and collaborators

University of Virginia

Lead sponsor

Duke University

Collaborator

The Hong Kong Polytechnic University

Collaborator